Verona Pharma plc (I9SA) - Total Assets
Based on the latest financial reports, Verona Pharma plc (I9SA) holds total assets worth €572.87 Million EUR (≈ $669.75 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Verona Pharma plc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Verona Pharma plc - Total Assets Trend (2016–2024)
This chart illustrates how Verona Pharma plc's total assets have evolved over time, based on quarterly financial data. See Verona Pharma plc (I9SA) net assets for net asset value and shareholders' equity analysis.
Verona Pharma plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Verona Pharma plc's total assets of €572.87 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 84.3% |
| Accounts Receivable | €31.50 Million | 6.6% |
| Inventory | €6.25 Million | 1.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €545.00K | 0.1% |
Asset Composition Trend (2016–2024)
This chart illustrates how Verona Pharma plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Verona Pharma plc (I9SA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verona Pharma plc's current assets represent 95.6% of total assets in 2024, an increase from 77.0% in 2016.
- Cash Position: Cash and equivalents constituted 84.3% of total assets in 2024, down from 86.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Verona Pharma plc Competitors by Total Assets
Key competitors of Verona Pharma plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Merus BV
NASDAQ:MRUS
|
USA | $771.99 Million |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
China | CN¥3.01 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866
|
China | CN¥17.39 Billion |
Verona Pharma plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.71 | 8.61 | 12.60 |
| Quick Ratio | 10.54 | 8.61 | 12.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €497.61 Million | €367.95 Million | €195.62 Million |
Verona Pharma plc - Advanced Valuation Insights
This section examines the relationship between Verona Pharma plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 32.46 |
| Latest Market Cap to Assets Ratio | 19.12 |
| Asset Growth Rate (YoY) | 53.9% |
| Total Assets | €474.24 Million |
| Market Capitalization | $9.07 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Verona Pharma plc's assets at a significant premium (19.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Verona Pharma plc's assets grew by 53.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Verona Pharma plc (2016–2024)
The table below shows the annual total assets of Verona Pharma plc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €474.24 Million ≈ $554.44 Million |
+53.91% |
| 2023-12-31 | €308.12 Million ≈ $360.23 Million |
+18.75% |
| 2022-12-31 | €259.47 Million ≈ $303.35 Million |
+39.06% |
| 2021-12-31 | €186.59 Million ≈ $218.14 Million |
-8.63% |
| 2020-12-31 | €204.21 Million ≈ $238.74 Million |
+245.06% |
| 2019-12-31 | €59.18 Million ≈ $69.19 Million |
-37.20% |
| 2018-12-31 | €94.23 Million ≈ $110.17 Million |
-22.10% |
| 2017-12-31 | €120.96 Million ≈ $141.41 Million |
+112.46% |
| 2016-12-31 | €56.93 Million ≈ $66.56 Million |
-- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more